Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

BRENDA Home
show all | hide all No of entries

Information on EC 2.3.1.97 - glycylpeptide N-tetradecanoyltransferase and Organism(s) Candida albicans and UniProt Accession P30418

for references in articles please use BRENDA:EC2.3.1.97
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
IUBMB Comments
The enzyme catalyses the transfer of myristic acid from myristoyl-CoA to the amino group of the N-terminal glycine residue in a variety of eukaryotic proteins. It uses an ordered Bi Bi reaction in which myristoyl-CoA binds to the enzyme prior to the binding of the peptide substrate, and CoA release precedes the release of the myristoylated peptide. The enzyme from yeast is profoundly affected by amino acids further from the N-terminus, and is particularly stimulated by a serine residue at position 5.
Specify your search results
Select one or more organisms in this record: ?
This record set is specific for:
Candida albicans
UNIPROT: P30418
Show additional data
Do not include text mining results
Include (text mining) results
Include results (AMENDA + additional results, but less precise)
Word Map
hide
The taxonomic range for the selected organisms is: Candida albicans
The enzyme appears in selected viruses and cellular organisms
Synonyms
n-myristoyltransferase, nmt-1, myristoyl-coa:protein n-myristoyltransferase, n-myristoyl transferase, nmt1p, n-myristoyltransferase 1, myristoyltransferase, canmt, myristoyl-coa protein n-myristoyltransferase, tbnmt, more
SYNONYM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
N-myristoyltransferase
-
myristoyl-CoA-protein N-myristoyltransferase
-
-
-
-
myristoyl-CoA:protein N-myristoyltransferase
-
-
myristoyl-coenzyme A:protein N-myristoyl transferase
-
-
-
-
myristoylating enzymes
-
-
-
-
myristoyltransferase, protein N-
-
-
-
-
N-myristoyl transferase
-
-
N-myristoyltransferase
-
-
peptide N-myristoyltransferase
-
-
-
-
protein N-myristoyltransferase
-
-
-
-
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
tetradecanoyl-CoA + an N-terminal-glycyl-[protein] = CoA + an N-terminal-N-tetradecanoylglycyl-[protein]
show the reaction diagram
myristoylation by NMT proceeds via an ordered bi-bi reaction mechanism in which binding of myristoyl-CoA generates a second binding pocket for the docking of the substrate protein. The myristate group from myristoyl-CoA is then transferred to the N-terminal glycine of the bound protein in a nucleophilic addition-elimination reaction. This is followed by stepwise release, first of the free CoA and then the N-myristoylated protein
-
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Acyl group transfer
-
-
-
-
amide bond formation
-
-
-
-
SYSTEMATIC NAME
IUBMB Comments
tetradecanoyl-CoA:N-terminal-glycine-[protein] N-tetradecanoyltransferase
The enzyme catalyses the transfer of myristic acid from myristoyl-CoA to the amino group of the N-terminal glycine residue in a variety of eukaryotic proteins. It uses an ordered Bi Bi reaction in which myristoyl-CoA binds to the enzyme prior to the binding of the peptide substrate, and CoA release precedes the release of the myristoylated peptide. The enzyme from yeast is profoundly affected by amino acids further from the N-terminus, and is particularly stimulated by a serine residue at position 5.
CAS REGISTRY NUMBER
COMMENTARY hide
110071-61-9
-
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
myristoyl-CoA + GLTISKLFRR
?
show the reaction diagram
-
-
-
?
myristoyl-CoA + GLTISKLFRR-NH2
?
show the reaction diagram
-
-
-
?
myristoyl-CoA + Gly-Ala-Arg-Ala-Ser-Val-Leu-Ser
N-myristoyl-Gly-Ala-Arg-Ala-Ser-Val-Leu-Ser + CoA
show the reaction diagram
-
-
-
-
?
myristoyl-CoA + Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg
N-myristoyl-Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg + CoA
show the reaction diagram
-
-
-
-
?
myristoyl-CoA + Gly-Asn-Ala-Ala-Ser-Ala-Arg-Arg
N-myristoyl-Gly-Asn-Ala-Ala-Ser-Ala-Arg-Arg + CoA
show the reaction diagram
-
-
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
show the reaction diagram
palmitoyl-CoA + glycylpeptide
N-palmitoylglycylpeptide + CoA
show the reaction diagram
-
no activity
-
-
?
tetradecanoyl-CoA + GLYASKLA
CoA + N-tetradecanoyl-GLYASKLA
show the reaction diagram
-
i.e. myristoyl-CoA
-
-
?
tetradecanoyl-CoA + Plasmodium falciparum ADP ribosylation factor 1 peptide
CoA + N-myristoylated Plasmodium falciparum ADP ribosylation factor 1 peptide
show the reaction diagram
-
model substrate, N-myristoylation of a glycine residue
-
-
ir
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
show the reaction diagram
-
-
-
-
?
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
IC50: 0.00000049 mM
(1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclopentanecarboxamide
IC50: 0.000015 mM
(1R,3S)-N-{2-[(cyclopeanthylcarbonyl)amino]-benzothiazol-6-yl}-3-[(2-naphthylmethyl) amino] cyclohexanecarboxamide
competitive with the substrate peptide and non-competitive with myristoyl-CoA. IC50: 0.49 nM
(1S,3R)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
IC50: above 0.00001 mM
(1S,3R)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclopentanecarboxamide
IC50: 0.000011mM
2-(acetylamino)-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
2-(benzylamino)-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
2-([2-[(2,3-difluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-([2-[(2,4-difluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-([2-[(2-fluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-([2-[(3-fluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-([2-[(4-chlorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-([2-[(4-fluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-([3-methyl-2-[(phenylsulfanyl)methyl]-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)ethanamine
-
2-amino-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
2-[(2-methylpropanoyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: 0.000046 mM
2-[(3-methyl-4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-yl)methoxy]benzonitrile
-
2-[(cyclobutylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: 0.000028 mM
2-[(cyclohexanecarbonyl)amino]-N-[(2-naphthylmethyl)amino]ethyl-benzothiazole-6-carboxamide
IC50: 0.0000344 mM
2-[(cyclohexylcarbonyl)amino]-1-methyl-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1H-benzimidazole-5-carboxamide
IC50: above 0.1 mM
2-[(cyclohexylcarbonyl)amino]-1-methyl-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1H-benzimidazole-6-carboxamide
IC50: above 0.1 mM
2-[(cyclohexylcarbonyl)amino]-N-(3-[[(naphthalen-2-ylmethyl)amino]methyl]benzyl)-1,3-benzothiazole-6-carboxamide
IC50: 0.0019 mM
2-[(cyclohexylcarbonyl)amino]-N-(4-[[(naphthalen-2-ylmethyl)amino]methyl]benzyl)-1,3-benzothiazole-6-carboxamide
IC50: above 0.1 mM
2-[(cyclohexylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-5-carboxamide
IC50: 0.0068 mM
2-[(cyclohexylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-7-carboxamide
IC50: 0.001 mM
2-[(cyclohexylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzoxazole-5-carboxamide
IC50: 0.0011 mM
2-[(cyclohexylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzoxazole-6-carboxamide
IC50: 0.00029 mM
2-[(cyclohexylcarbonyl)amino]-N-[3-[(naphthalen-2-ylmethyl)amino]propyl]-1,3-benzothiazole-6-carboxamide
IC50: 0.00011 mM
2-[(cyclohexylcarbonyl)amino]-N-[4-[(naphthalen-2-ylmethyl)amino]butyl]-1,3-benzothiazole-6-carboxamide
IC50: 0.000074 mM
2-[(cyclohexylcarbonyl)amino]-N-[5-[(naphthalen-2-ylmethyl)amino]pentyl]-1,3-benzothiazole-6-carboxamide
IC50: 0.0003 mM
2-[(cyclohexylmethyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: above 0.001 mM
2-[(cyclopentylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: 0.000023 mM
2-[[(2,5-dimethoxyphenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: 0.00031 mM
2-[[(2-chloropyridin-3-yl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
2-[[(3,4-dichlorophenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
2-[[(4-chlorophenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
2-[[3-methyl-2-(2-phenylethyl)-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmethyl)ethanamine
-
2-[[3-methyl-2-(phenoxymethyl)-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmethyl)ethanamine
-
3-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-[(pyridin-3-yl)methyl]propan-1-amine
compound displays hydrogen bonds between the benzofuran oxygen and the His227 residues as well as between the nitrogen from 2-piridinyl ring at C4 side chain and the Tyr119. The 2-pyridinyl ring interacts with Phe117 as well as the trifluorobenzene, at C2 side chain, interacts both with Phe115 and Phe240
4-[(3-methyl-4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-yl)methoxy]benzonitrile
-
ethyl 3-(1-methylethyl)-4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-carboxylate
-
ethyl 3-cyclopropyl-4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-carboxylate
-
ethyl 3-ethyl-4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-carboxylate
-
ethyl 3-methyl-4-(3-piperidin-1-ylpropoxy)-1-benzofuran-2-carboxylate
-
ethyl 3-methyl-4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-carboxylate
-
ethyl 4-[2-(benzylamino)ethoxy]-3-methyl-1-benzofuran-2-carboxylate
-
ethyl 4-[2-(tert-butylamino)ethoxy]-3-methyl-1-benzofuran-2-carboxylate
-
ethyl 4-[2-hydroxy-3-[(2-methylpropyl)amino]propoxy]-3-methyl-1-benzofuran-2-carboxylate
-
ethyl 4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-carboxylate
-
ethyl 4-[3-(tert-butylamino)propoxy]-3-methyl-1-benzofuran-2-carboxylate
-
ethyl 4-[3-[(2,2-dimethylpropyl)amino]-2-hydroxypropoxy]-3-methyl-1-benzofuran-2-carboxylate
-
ethyl 4-[4-(tert-butylamino)butoxy]-3-methyl-1-benzofuran-2-carboxylate
-
ethyl 4-[[5-(tert-butylamino)pentyl]oxy]-3-methyl-1-benzofuran-2-carboxylate
-
N-(6-[[N-(biphenyl-4-ylmethyl)-b-alanyl]amino]-1,3-benzothiazol-2-yl)cyclopentanecarboxamide
IC50: 0.00016 mM
N-(6-[[N-(naphthalen-2-ylmethyl)-b-alanyl]amino]-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
IC50: 0.00018 mM
N-(6-[[N-(naphthalen-2-ylmethyl)glycyl]amino]-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
IC50: 0.0023 mM
N-[(3-methyl-4-[2-[(pyridin-3-ylmethyl)amino]ethoxy]-1-benzofuran-2-yl)oxy]aniline
-
N-[(pyridin-3-yl)methyl]-3-([2-[(2,3,4-trifluorophenoxy)methyl]-1,3-benzothiazol-7-yl]oxy)propan-1-amine
compound forms hydrogen bonds between the nitrogen from C4 side chain and the Leu421 as well as between the benzothiazole nitrogen and His227
N-[2-[(2-methylpropanoyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
IC50: 0.0000033 mM
N-[2-[(cyclobutylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
IC50: 0.0000023 mM
N-[2-[(cyclohexylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
IC50: 0.0000081 mM
N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
IC50: 0.0000012 mM
N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[[(4-phenylcyclohexa-1,5-dien-1-yl)methyl]amino]cyclohexanecarboxamide
IC50: 0.00013 mM
N-[2-[(cyclopropylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
IC50: 0.0000024 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-(propanoylamino)-1,3-benzothiazole-6-carboxamide
IC50: 0.00013 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-([[4-(trifluoromethyl)phenyl]carbonyl]amino)-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(phenylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
IC50: 0.00016 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(pyrazin-2-ylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
IC50: 0.00073 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(pyridin-2-ylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(pyridin-2-ylmethyl)amino]-1,3-benzothiazole-6-carboxamide
IC50: above 0.01 mM
N-[6-([3-[(naphthalen-2-ylmethyl)amino]azetidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
IC50: 0.000065 mM
N-[6-([3-[(naphthalen-2-ylmethyl)amino]piperidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
IC50: 0.00021 mM
N-[6-([3-[(naphthalen-2-ylmethyl)amino]pyrrolidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
IC50: 0.00019 mM
N-[6-([4-[(naphthalen-2-ylmethyl)amino]butanoyl]amino)-1,3-benzothiazol-2-yl]cyclopentanecarboxamide
IC50: 0.000015 mM
N-[6-([4-[(naphthalen-2-ylmethyl)amino]piperidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
IC50: 0.0005 mM
N-[6-[(4-[[(naphthalen-2-ylmethyl)amino]methyl]piperidin-1-yl)carbonyl]-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
IC50: 0.000026 mM
tert-butyl [6-([2-[(naphthalen-2-ylmethyl)amino]ethyl]carbamoyl)-1,3-benzothiazol-2-yl]carbamate
IC50: above 0.01 mM
trans-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
IC50: 0.000034 mM
(1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
(4S,5aS,12aS)-2-carbamoyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-5-yl acetate
-
-
1-hydroxy-2-[(1-methylethyl)amino]ethyl 2,6-dihydroxybenzoate
-
-
2-(diethylamino)ethyl 2-[(cyclohexylcarbonyl)amino]-1,3-benzothiazole-6-carboxylate
-
-
2-([[4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-[([(1R,3S)-3-[(1-benzofuran-6-ylmethyl)amino]cyclohexyl]carbonyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
2-[([(1R,3S)-3-[(1H-indol-6-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
-
3,3'-[(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methanediyl]bis(6-hydroxybenzoic acid)
-
-
3-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)propan-1-amine
-
-
4-(4,5-dihydroxy-9-methyl-3-oxo-1,3,3a,4,9,9a-hexahydronaphtho[2,3-c]furan-1-yl)-2,5,6-trihydroxycyclohexa-2,4-diene-1-carboxamide
-
-
benzyl-{3-[2-(2-ethoxymethyl-benzofuran-5-ylmethoxymethyl)-3-methyl-benzofuran-4-yloxy]-propyl}-amine
-
-
cis-4-[(naphthalen-2-ylmethyl)amino]-N-(6-pyridin-2-yl-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
-
-
cis-N-(6-fluoro-1,3-benzothiazol-2-yl)-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
cis-N-1,3-benzothiazol-2-yl-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
-
ethyl 3-methyl-4-[3-[(pyridin-3-ylmethyl)amino]propoxy]-1-benzofuran-2-carboxylate
-
-
ethyl 4-[2-hydroxy-3-(isopropylamino)propoxy]-3-methyl-1-benzofuran-2-carboxylate
-
-
N-([4-[5-(2-methyl-1H-imidazol-1-yl)pentyl]phenyl]acetyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
-
-
N-[(1R)-1-[3-(3-aminopropyl)-4-(2-cyclohexylethoxy)benzyl]-2-hydroxyethyl]-2-[4-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetamide
-
-
S-(2-oxo)pentadecyl-CoA
-
-
SC-58272
{3-[2-(1H-imidazol-2-yl)-3-methyl-benzofuran-4-yloxy]-propyl}-pyridin-3-ylmethyl-amine
-
-
{3-[2-(2,3-difluoro-phenoxymethyl)-3-methyl-benzofuran-4-yloxy]-propyl}-pyridin-3-ylmethyl-amine
-
-
{3-[2-(2-ethoxymethyl-benzofuran-5-yloxymethyl)-3-methyl-benzofuran-4-yloxy]-propyl}-pyridin-3-ylmethyl-amine
-
-
additional information
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.000000362
GLTISKLFRR-NH2
-
0.00000283
myristoyl-CoA
-
0.017
Gly-Ala-Arg-Ala-Ser-Val-Leu-Ser
-
-
0.6
Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg
-
-
0.006
Gly-Asn-Ala-Ala-Ser-Ala-Arg-Arg
-
-
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
additional information
additional information
-
-
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00000049
(1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
Candida albicans
IC50: 0.00000049 mM
0.000015
(1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclopentanecarboxamide
Candida albicans
IC50: 0.000015 mM
0.00000049
(1R,3S)-N-{2-[(cyclopeanthylcarbonyl)amino]-benzothiazol-6-yl}-3-[(2-naphthylmethyl) amino] cyclohexanecarboxamide
Candida albicans
competitive with the substrate peptide and non-competitive with myristoyl-CoA. IC50: 0.49 nM
0.00001
(1S,3R)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
Candida albicans
IC50: above 0.00001 mM
0.000011
(1S,3R)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclopentanecarboxamide
Candida albicans
IC50: 0.000011mM
0.01
2-(acetylamino)-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.01 mM
0.01
2-(benzylamino)-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.01 mM
0.01
2-amino-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.01 mM
0.000046
2-[(2-methylpropanoyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.000046 mM
0.000028
2-[(cyclobutylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.000028 mM
0.0000344
2-[(cyclohexanecarbonyl)amino]-N-[(2-naphthylmethyl)amino]ethyl-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.0000344 mM
0.1
2-[(cyclohexylcarbonyl)amino]-1-methyl-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1H-benzimidazole-5-carboxamide
Candida albicans
IC50: above 0.1 mM
0.1
2-[(cyclohexylcarbonyl)amino]-1-methyl-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1H-benzimidazole-6-carboxamide
Candida albicans
IC50: above 0.1 mM
0.0019
2-[(cyclohexylcarbonyl)amino]-N-(3-[[(naphthalen-2-ylmethyl)amino]methyl]benzyl)-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.0019 mM
0.1
2-[(cyclohexylcarbonyl)amino]-N-(4-[[(naphthalen-2-ylmethyl)amino]methyl]benzyl)-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.1 mM
0.0068
2-[(cyclohexylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-5-carboxamide
Candida albicans
IC50: 0.0068 mM
0.001
2-[(cyclohexylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-7-carboxamide
Candida albicans
IC50: 0.001 mM
0.0011
2-[(cyclohexylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzoxazole-5-carboxamide
Candida albicans
IC50: 0.0011 mM
0.00029
2-[(cyclohexylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzoxazole-6-carboxamide
Candida albicans
IC50: 0.00029 mM
0.00011
2-[(cyclohexylcarbonyl)amino]-N-[3-[(naphthalen-2-ylmethyl)amino]propyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.00011 mM
0.000074
2-[(cyclohexylcarbonyl)amino]-N-[4-[(naphthalen-2-ylmethyl)amino]butyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.000074 mM
0.0003
2-[(cyclohexylcarbonyl)amino]-N-[5-[(naphthalen-2-ylmethyl)amino]pentyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.0003 mM
0.001
2-[(cyclohexylmethyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.001 mM
0.000023
2-[(cyclopentylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.000023 mM
0.00031
2-[[(2,5-dimethoxyphenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.00031 mM
0.01
2-[[(2-chloropyridin-3-yl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.01 mM
0.01
2-[[(3,4-dichlorophenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.01 mM
0.01
2-[[(4-chlorophenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.01 mM
0.00016
N-(6-[[N-(biphenyl-4-ylmethyl)-b-alanyl]amino]-1,3-benzothiazol-2-yl)cyclopentanecarboxamide
Candida albicans
IC50: 0.00016 mM
0.00018
N-(6-[[N-(naphthalen-2-ylmethyl)-b-alanyl]amino]-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
Candida albicans
IC50: 0.00018 mM
0.0023
N-(6-[[N-(naphthalen-2-ylmethyl)glycyl]amino]-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
Candida albicans
IC50: 0.0023 mM
0.0000033
N-[2-[(2-methylpropanoyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
Candida albicans
IC50: 0.0000033 mM
0.0000023
N-[2-[(cyclobutylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
Candida albicans
IC50: 0.0000023 mM
0.0000081
N-[2-[(cyclohexylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
Candida albicans
IC50: 0.0000081 mM
0.0000012
N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
Candida albicans
IC50: 0.0000012 mM
0.00013
N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[[(4-phenylcyclohexa-1,5-dien-1-yl)methyl]amino]cyclohexanecarboxamide
Candida albicans
IC50: 0.00013 mM
0.0000024
N-[2-[(cyclopropylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
Candida albicans
IC50: 0.0000024 mM
0.01
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.01 mM
0.00013
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-(propanoylamino)-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.00013 mM
0.01
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-([[4-(trifluoromethyl)phenyl]carbonyl]amino)-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.01 mM
0.00016
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(phenylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.00016 mM
0.00073
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(pyrazin-2-ylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: 0.00073 mM
0.01
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(pyridin-2-ylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.01 mM
0.01
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(pyridin-2-ylmethyl)amino]-1,3-benzothiazole-6-carboxamide
Candida albicans
IC50: above 0.01 mM
0.000065
N-[6-([3-[(naphthalen-2-ylmethyl)amino]azetidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
Candida albicans
IC50: 0.000065 mM
0.00021
N-[6-([3-[(naphthalen-2-ylmethyl)amino]piperidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
Candida albicans
IC50: 0.00021 mM
0.00019
N-[6-([3-[(naphthalen-2-ylmethyl)amino]pyrrolidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
Candida albicans
IC50: 0.00019 mM
0.000015
N-[6-([4-[(naphthalen-2-ylmethyl)amino]butanoyl]amino)-1,3-benzothiazol-2-yl]cyclopentanecarboxamide
Candida albicans
IC50: 0.000015 mM
0.0005
N-[6-([4-[(naphthalen-2-ylmethyl)amino]piperidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
Candida albicans
IC50: 0.0005 mM
0.000026
N-[6-[(4-[[(naphthalen-2-ylmethyl)amino]methyl]piperidin-1-yl)carbonyl]-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
Candida albicans
IC50: 0.000026 mM
0.01
tert-butyl [6-([2-[(naphthalen-2-ylmethyl)amino]ethyl]carbamoyl)-1,3-benzothiazol-2-yl]carbamate
Candida albicans
IC50: above 0.01 mM
0.000034
trans-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
Candida albicans
IC50: 0.000034 mM
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.000024
-
purified native enzyme
0.000149
-
purified recombinant enzyme
additional information
-
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
45000
-
1 * 45000, SDS-PAGE
46000
-
mass spectroscopy
51880
-
calculation from gene sequence
additional information
-
amino acid sequence, alignment
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
monomer
-
1 * 45000, SDS-PAGE
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
comparative binding site analysis and molecular docking studies of Leishmania major and Candida albicans NMT and molecular docking studies with benzoheterocyclic analogues
ternary complex formation incubation of protein, 60 mg/ml, with 5fold molar of myristoyl-CoA and inhibitor SC-58272 for a few hours, hanging drop at 4°C, from 0.2 M ammonium acetate, 50 mM HEPES, pH 7.5, 10-12% polyethylene glycol 3350, 2-3 weeks, crystal structure determination by X-ray diffraction analysis
-
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
native enzyme, and recombinant enzyme from Escherichia coli
-
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
expression in Escherichia coli
expression in Escherichia coli strain BL21
-
expression in Escherichia coli, DNA sequence determination
-
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
drug development
-
the enzyme is a drug target
medicine
-
target for antiviral and antifungal therapy
molecular biology
-
the enzyme can be used for protein N-myristoylation as a tag labeling technique in recombinant expresssion systems. CaNMT is an effective tool for in vitro and in vivo transfer of an azide-modified acid to the N-terminus of a polypeptide derived from a species entirely unrelated to Candida albicans
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Wiegand, R.C.; Carr, C.; Minnerly, J.C.; Pauley, A.M.; Carron, C.P.; Langner, C.A.; Duronio, R.J.; Gordon, J.I.
The Candida albicans myristoyl-CoA:protein N-myristoyltransferase gene. Isolation and expression in Saccharomyces cerevisiae and Escherichia coli
J. Biol. Chem.
267
8591-8598
1992
Candida albicans, Saccharomyces cerevisiae
Manually annotated by BRENDA team
Sogabe, S.; Masubuchi, M.; Sakata, K.; Fukami, T.A.; Morikami, K.; Shiratori, Y.; Ebiike, H.; Kawasaki, K.; Aoki, Y.; Shimma, N.; D'Arcy, A.; Winkler, F.K.; Banner, D.W.; Ohtsuka, T.
Crystal structures of Candida albicans N-myristoyltransferase with two distinct inhibitors
Chem. Biol.
9
1119-1128
2002
Candida albicans
Manually annotated by BRENDA team
Ebara, S.; Naito, H.; Nakazawa, K.; Ishii, F.; Nakamura, M.
FTR1335 is a novel synthetic inhibitor of Candida albicans N-myristoyltransferase with fungicidal activity
Biol. Pharm. Bull.
28
591-595
2005
Candida albicans (P30418), Candida albicans
Manually annotated by BRENDA team
Yamazaki, K.; Kaneko, Y.; Suwa, K.; Ebara, S.; Nakazawa, K.; Yasuno, K.
Synthesis of potent and selective inhibitors of Candida albicans N-myristoyltransferase based on the benzothiazole structure
Bioorg. Med. Chem.
13
2509-2522
2005
Candida albicans (P30418), Candida albicans, Homo sapiens (P30419)
Manually annotated by BRENDA team
Heal, W.; Wickramasinghe, S.; Bowyer, P.; Holder, A.; Smith, D.; Leatherbarrow, R.; Tate, E.
Site-specific N-terminal labelling of proteins in vitro and in vivo using N-myristoyl transferase and bioorthogonal ligation chemistry
Chem. Commun. (Camb. )
8
480-482
2008
Candida albicans
-
Manually annotated by BRENDA team
Bowyer, P.; Tate, E.; Leatherbarrow, R.; Holder, A.; Smith, D.; Brown, K.
N-myristoyltransferase: A prospective drug target for protozoan parasites
ChemMedChem
3
402-408
2008
Histoplasma capsulatum, Saccharomyces cerevisiae, Candida albicans, Cryptococcus neoformans, Leishmania major, Plasmodium falciparum, Trypanosoma brucei
Manually annotated by BRENDA team
Deokar, H.; Puranik, P.; Kulkarni, V.
QSAR analysis of N-myristoyltransferase inhibitors: antifungal activity of benzofurans
Med. Chem. Res.
18
206-220
2009
Candida albicans (P30418)
-
Manually annotated by BRENDA team
Junqueira, L.; Da Costa, M.; Rando, D.
N-myristoyltransferases as antileishmanial targets A piggyback approach with benzoheterocyclic analogues
Braz. J. Pharm. Sci.
55
e18087
2019
Candida albicans (P30418), Leishmania major (Q4Q5S8)
-
Manually annotated by BRENDA team